Keros Therapeutics

KROSNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$187.565 M

$9.46 -12.65%

Close of 6 Nov 2026

As of 6 Nov 2026, Keros Therapeutics (KROS) has a market capitalization of $187.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$243.9M

#2206 by revenue

Earnings

$87.0M

#1353 by earnings

Shares outstanding

19,624,374

Latest filing cover page

P/E ratio

2.2

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#250Pyxis OncologyPYXS$193.1M
#251ProQR TherapeuticsPRQR$188.4M
#252Keros TherapeuticsKROS$187.6M
#253Entrada TherapeuticsTRDA$176.8M
#254Natures Sunshine ProductsNATR$176.6M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Keros Therapeutics, worth $10.3K. Grants and option exercises are excluded.

Jean Jacques Bienaime$10.3K
1,000 shares at $10.27 on 17 Aug 2026 · filed 19 Aug 2026

What if Keros Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,424,149

Per share 150,544× higher

Bitcoin $1.53T

$77,058.23

Per share 8,146× higher

Apple $5.02T

$252,974.99

Per share 26,742× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Keros Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.